Resistance to human immunodeficiency virus type 1 protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2775-2783

  Boden, Daniel ^a   Markowitz, Martin ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; CLINICAL TRIAL; CROSS RESISTANCE; DRUG STRUCTURE; ENZYME ACTIVE SITE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 0031724008     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2775     Document Type: Review

References (97)

1. Appelt, K. R., J. Bacquet, C. Bartlett, C. L. J. Booth, S. T. Freer, M. M. Fuhry, M. R. Gehring, S. M. Herrmann, E. F. Rowland, C. A. Janson, T. R. Jones, C. C. Ran, V. Kathardekar, K. K. Lewis, G. P. Marzoni, D. A. Mathews, C. Mohr, E. W. Moomaw, C. A. Morse, S. J. Oatley, R. C. Ogden, M. R. Reddy, S. H. Reich, W. S. Schoettlin, W. W. Smith, M. D. Varney, J. E. Villafranca, R. W. Ward, S. Webber, S. E. Webber, K. M. Welsh, and J. White. 1991. Design of enzyme inhibitors using iterative protein crystallographic analysis. J. Med. Chem. 34:1925-1928.
2. Cameron, D. W., A. J. Japour, Y. Xu, A. Hsu, C. Cohen, C. Farthing, S. Follansbee, M. Markowitz, J. Mellors, D. Poretz, J. B. Angel, D. Ho, D. McMahon, V. Devanarayan, R. Rode, M. Salgo, D. Kempf, R. Granneman, J. M. Leonard, and E. Sun. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. Submitted for publication.
3. Chen, Z., Y. Li, D. Hall, E. Chen, and L. C. Kuo. 1995. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270:21433-21436.
4. Chong, K.-T., and P. J. Pagano. 1997. In vitro combination of PNU-140690, a human immunodeficiency virus protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob. Agents Chemother. 41:2367-2373.
5. Coffin, J. M. 1995. HIV population in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
6. Collier, A. C., R. Coombs, D. A. Schoenfeld, R. L. Bassett, M. S. Joseph Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichmann, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334:1011-1017.
7. Collins, J. R., S. K. Burt, and J. W. Erickson. 1995. Flap opening in HIV-1 protease simulated by activated molecular dynamics. Nat. Struct. Biol. 2:334-338.
8. Collins, J. R., S. K. Burt, and J. W. Erickson. 1995. Activated dynamics of flap opening in HIV-1 protease. Adv. Exp. Med. Biol. 362:455-460.
9. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
10. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
11. Condra, J. H., D. J. Holder, D. J. Graham, M. Shivaprakash, D. T. Laird, W. A. Schleif, J. A. Chodakewitz, and E. A. Emini. 1997. Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir, abstr. 47, p. 31. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Fla.
12. Cornelissen, M., G. Kampinga, F. Zorgdrager, J. Goudsmit, and the UNAIDS Network for HIV Isolation and Characterization. 1996. Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes. J. Virol. 70:8209-8212.
13. Cornelissen, M., R. van den Burg, F. Zorgdrager, V. Lukashov, and J. Goudsmit. 1997. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J. Virol. 71:6348-6358.
14. Craig, I. C., I. B. Duncan, N. A. Roberts, and L. Whittaker. 1993. Ro 31-8959, an inhibitor of HIV proteinase, appears relatively refractory to the generation of virus mutants with reduced sensitivity, abstr. PO-A26-0694, p. 243. In Abstracts of the 9th International Conference on AIDS, Berlin, Germany.
15. Crawford, S., and S. P. Goff. 1985. A deletion mutation in the 5′ part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J. Virol. 53:899-907.
16. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Guidiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. G. Aguado, J. G. De Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. M. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533.
17. Darke, P. L., R. F. Nutt, S. F. Brady, V. M. Garsky, T. M. Ciccarone, C. T. Leu, P. K. Lumma, R. M. Freidinger, D. F. Veber, and I. S. Sigal. 1988. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun. 156:297-303.
18. Debouck, C., M. A. Navia, P. M. D. Fitzgerald, B. M. McKeever, C.-T. Leu, J. C. Heimbach, W. K. Herber, I. S. Sigal, P. L. Darke, and J. P. Springer. 1987. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc. Natl. Acad. Sci. USA 84:8903-8906.
19. De Clerq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
20. Diaz, R. S., E. C. Sabino, A. Mayer, J. W. Mosley, M. P. Bush, and The Transfusion Safety Study Group. 1995. Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. J. Virol. 69:3273-3281.
21. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
22. Dreyer, G. B., D. M. Lambert, T. D. Meek, T. J. Carr, T. A. Tomaszek, Jr., A. V. Fernandez, H. Bartus, E. Cacciavillani, A. M. Hassell, and M. Minnich. 1992. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. Biochemistry 31:6646-6659.
23. Dreyer, G. B., J. C. Boehm, B. Chenera, R. L. DesJarlais, A. M. Hassell, T. D. Meek, T. A. J. Tomaszek, and M. Lewis. 1993. A symmetric inhibitor hinds HIV-1 protease asymmetrically. Biochemistry 32:937-947.
24. Dulioust, A., S. Paulous, L. Guillemot, F. Bouè, P. Galanaud, and F. Clavel. 1997. Selection of saquinavir resistant mutants by indinavir following a switch from saquinavir, abstr. 16, p. 11. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Fla.
25. Duncan, I. B., H. Jacobsen, S. Owen, and N. A. Roberts. 1996. Reduced HIV sensitivity during treatment with proteinase inhibitor saquinavir, abstr. 155. In Abstracts of the 3rd Conference of Retroviruses and Opportunistic Infections, Washington, D.C.
26. Eastman, P. S., I. B. Duncan, C. Gee, and E. Race. 1997. Acquisition of genotypic mutations associated with reduced susceptibility to protease inhibitors during saquinavir monotherapy, abstr. 30, p. 19. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Fla.
27. Eberle, J., B. Bechowsky, D. Rose, U. Hauser, K. vonder Helm, L. Guertler, and H. Nitschko. 1995. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res. Hum. Retroviruses 11:671-676.
28. Emini, E. A., W. A. Schleif, P. Deutsch, and J. H. Condra. 1996. In vivo resistance of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Antiviral Chemother. 4:327-331.
29. Ermolieff, J., L. Hong, X. Lin, S. Foundling, J. A. Hartsuck, and J. Tang. 1997. Kinetic and structural basis of saquinavir resistance of HIV-1 protease mutants, abstr. 14, p. 9. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Fla.
30. Gottlinger, H. G., J. G. Sodroski, and W. A. Haseltine. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86: 5781-5785.
31. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
32. Hertogs, K., M.-P. deBethune, V. Miller, T. Ivens, P. Schel, A. van Cauwenberge, C. van den Eynde, V. van Gerwen, H. Azijn, M. van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
33. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
34. 2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
35. Holland, J., K. Spindler, F. Horodyski, E. Grabau, S. Nichol, and S. Vander-Pol. 1982. Rapid evolution of RNA genomes. Science 215:1577-1585.
36. Hosur, M. V., T. N. Bhat, D. J. Kempf, E. T. Baldwin, B. Liu, S. Gulnik, N. E. Wideburg, D. W. Norbeck, K. Appell, and J. W. Erickson. 1994. Influence of stereochemistry on activity and binding modes for C2 symmetry-based-inhibitors of HIV-1 protease. J. Am. Chem. Soc. 116:847-855.
37. Huff, J. R. 1991. HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 34:2305-2314.
38. Ives, K. J., H. Jacobsen, S. A. Galpin, M. M. Garaev, L. Dorrell, J. Mous, K. Bragman, and J. N. Weber. 1997. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J. Antimicrob. Chemother. 39:771-779.
39. Jacks, T., M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, and H. E. Varmus. 1998. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331:280-283.
40. 2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
41. Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Kroehn, I. B. Duncan, and J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutant with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534.
42. Jacobsen, H., M. Hangi, M. Ott, I. B. Duncan, S. Owen, M. Andreoni, S. Vella, and J. Mous. 1996. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, frequencies. J. Infect. Dis. 173:1379-1387.
43. Kaldor, S. W., V. J. Kalish, J. F. Davies, B. V. Shetty, J. E. Fritz, K. Appelt, J. A. Burgess, K. M. Campanale, N. Y. Chirgadze, D. K. Clawson, B. A. Dressman, S. D. Hatch, D. A. Khalil, M. B. Kosa, P. P. Lubbehusen, M. A. Muesing, A. K. Patick, S. H. Reich, K. S. Su, and J. H. Tatlock. 1997. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:3979-3985.
44. Kaplan, A. H., J. A. Zack, M. Knigge, D. A. Paul, D. J. Kempf, D. W. Norbeck, and R. Swanstrom. 1993. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67:4050-4055.
45. Katoh, I., Y. Yoshinaka, A. Rein, M. Shibuya, T. Odaka, and S. Oroszlan. 1985. Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity. Virology 145:280-292.
46. Kim, E. E., C. T. Baker, M. D. Dwyer, M. A. Murcko, B. G. Rao, R. D. Tung, and M. A. Navia. 1995. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1181-1182.
47. Kohl, N. E., R. E. Diehl, E. Rands, L. J. Davis, M. G. Hanobik, B. Wolanski, and R. A. Dixon. 1991. Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles. J. Virol. 65:3007-3014.
48. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnik, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
49. Kotler, M., R. A. Katz, W. Danho, J. Leis, and A. M. Skalka. 1988. Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc. Natl. Acad. Sci. USA 85:4185-4189.
50. Kramer, R. A., M. D. Schaber, A. M. Skalka, K. Ganguly, F. Wong-Staal, and E. P. Reddy. 1986. HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 231:1580-1584.
51. Kuroda, M. J., M. A. El-Farrash, S. Cloudhury, and S. Harada. 1995. Impaired infectivity of HIV-1 after a single point mutation in the pol gene to escape the effect of a protease inhibitor in vitro. Virology 210:212-216.
52. Lal, R., A. Hsu, G. R. Granneman, T. El-Shoubargy, M. Johnson, W. Lam, L. Manning, A. Japour, and Sun E. Abbott Laboratories. 1998. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir, abstr. 647, p. 201. In Abstracts of the 5th Conference on Retrovirus and Opportunistic Infections, Chicago, Ill.
53. Lambert, D. M., S. R. Petteway, Jr., C. E. McDanal, T. K. Hart, J. J. Leary, G. B. Dreyer, T. D. Meek, P. J. Bugelski, D. P. Bolognesi, B. W. Metcalf, and T. J. Matthews. 1992. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob. Agents Chemother. 36:982-988.
54. Lillehoj, E. P., F. H. R. Salazar, R. J. Mervis, M. G. Raum, H. W. Chan, N. Ahmad, and S. Venkatesan. 1988. Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J. Virol. 62:3053-3058.
55. Lin, Y., X. Lin, L. Hong, S. Foundling, R. L. Heinrikson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B. M. Dunn, and J. Tang. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry 34:1143-1152.
56. Mansky, L. M., and H. M. Temin. 1996. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
57. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
58. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
59. Maschera, B., G. Darby, G. Palú, L. L. Wright, M. Tisdale, R. Meyers, E. D. Blair, and E. S. Furfine. 1996. Human immunodeficiency virus. Mutations in the viral protease that confers resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271: 33231-33235.
60. Miller, M., J. Schneider, B. K. Sathyanarayana, M. V. Toth, G. R. Marshall, L. Clawson, L. Selk, S. B. Kent, and A. Wlodawer. 1989. Structure of complex of synthetic HIV-1 protease with a substrate base inhibitor at 2.3 Å resolution. Science 246:1149-1152.
61. Mo, H., M. Markowitz, and D. D. Ho. 1995. Pattern of specific mutations that confer resistance to a panel of protease inhibitors, ahstr. 188, p. 89. In Abstracts of the 2nd National Conference on Human Retroviruses and Related Infections, Washington, D.C.
62. Molla, A., M. Korneyeva, T. Chernyavskiy, R. Colgrove, P. Chung, A. Japour, J. Mellors, Y. Xu, R. Rode, A. Hsu, G. R. Granneman, J. Kempf, J. Leonard, and the M96-462 Study Team. 1998. Characterization of HIV-1 protease mutations, compliance and drug concentrations in patients who have an HIV RNA rebound on ritonavir-saquinavir, abstr. 83, p. 54. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Fla.
63. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. O. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
64. Molla, A. Personal communication.
65. Mous, J., F. Brun-Vezinet, I. B. Duncan, M. Haenggi, H. Jacobsen, and S. Vella. 1994. Characterization of in vivo selected HIV-1 variants with reduced sensitivity to proteinase inhibitor saquinavir, abstr. 515B, p. 90. In Abstracts of the 10th International Conference on AIDS, Yokohama, Japan.
66. Murphy, R., V. Degruttola, R. Gulick, R. D'Aquila, J. Eron, J. P. Sommadossi, L. Smeaton, J. Currier, R. Tung, and D. Kuritzkes. 1998. 141W94 with or without zidovudine/3TC in patients with no prior protease inhibitor or 3TC therapy-ACTG 347, abstr. 512, p. 175. In Abstracts of the 5th Conference on Retrovirus and Opportunistic Infections, Chicago, Ill.
67. Navia, M. A., P. M. D. Fitzgerald, B. M. McKeever, C.-T. Leu, J. C. Heimbach, W. K. Herber, I. S. Sigal, P. L. Darke, and J. P. Springer. 1989. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337:615-620.
68. Parkin, N., J. Whitcomb, D. Smith, T. Tian, K. Limoli, Y. S. Lie, G. Winslow, T. Wrin, D. Capon, and C. J. Petropoulos. 1997. The use of a rapid phenotypic HIV-1 drug resistance and susceptibility assay in analyzing the emergence of drug-resistant virus during triple combination therapy, abstr. LB-1, p. 7. In Program addendum of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Toronto, Canada.
69. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, R. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
70. Patick, A. K., T. J. Boritzki, and L. A. Bloom. 1997. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 41:2159-2164.
71. Patick, A. K., H. Ho, M. Markowitz, K. Appelt, B. Wu, L. Musick, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
72. Patick, A. K., M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. Kuritzkes, D. D. Ho, and M. Markowitz. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor, nelfinavir. Submitted for publication.
73. Pazhanisamy, S., C. M. Stuver, A. B. Cullinan, N. Margolin, and B. G. Rao. 1996. Kinetic characterization of human immunodeficiency virus type 1 protease resistant variants. J. Biol. Chem. 271:17979-17985.
74. Peng, C., B. K. Ho, T. W. Chang, and N. T. Chang. 1989. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63:2550-2556.
75. Pettit, S. C., S. F. Michael, and R. Swanstrom. 1993. The specificity of the HIV-1 protease. Perspect. Drug Discov. Des. 1:69-83.
76. Poppe, S. M., D. E. Slade, K.-T. Chong, R. R. Hinshaw, P. J. Pagano, M. Markowitz, D. D. Ho, H. Mo, R. R. Gorman III, T. J. Dueweke, S. Thaisrivongs, and W. G. Tarpley. 1997. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41:1058-1063.
77. Richards, A. D., R. Roberts, B. M. Dunn, M. C. Graves, and J. Kay. 1989. Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett. 247:113.
78. Richman, D. D. 1993. HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 32:149-164.
79. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Kröhn, R. W. Lambert, J. H. Merett, J. S. Mills, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:338-361.
80. Robertson, D. L., P. M. Sharp, F. E. McCutchan, and B. H. Hahn. 1995. Recombination in HIV-1. Nature 374:124-126.
81. Schechter, I., and A. Berger. 1967. On the size of the active side in proteases. Biochem. Biophys. Res. Commun. 27:157.
82. Schmit, J.-C., L. Ruiz, B. Clotet, A. Raventos, J. Tor, J. Leonard, J. Desmyter, E. De Clerq, and A. M. Vandamme. 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.
83. Schock, H. B., V. M. Garsky, and L. C. Kuo. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. J. Biol. Chem. 271:31957-31963.
84. Shetty, B. V., M. B. Kosa, D. A. Khalil, and S. Webber. 1996. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:110-114.
85. St. Clair, M. H. S., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. M. Sadler, M. R. Blum, and G. Painter. 1996. In vitro activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 29:53-56.
86. Stewart, L., G. Schatz, and V. M. Vogt. 1990. Properties of avian retrovirus particles defective in viral protease. J. Virol. 64:5076-5092.
87. Tisdale, M., R. E. Myers, B. Maschera, N. R. Parry, N. M. Oliver, and E. D. Blair. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.
88. Toh, H., M. Ono, K. Saigo, and T. Miyata. 1985. Retroviral protease-like sequence in the yeast transposon Ty 1. Nature 315:691.
89. Tozser, J., A. Gustchina, I. T. Weber, I. Blaha, E. M. Wondrak, and S. Oroszlan. 1991. Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett. 279:356-360.
90. Turriziani, O., G. Antonelli, H. Jacobsen, J. Mous, E. Riva, M. Pistello, and F. Dianzani. 1994. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol. 38:297-298.
91. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovich, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524, an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
92. Vella, S., C. Galluzzo, G. Giannini, M. F. Pirillo, I. Duncan, H. Jacobsen, M. Andreoni, L. Sarmati, and L. Ercoli. 1996. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res. 29:91-93.
93. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. S. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
94. Winters, M. A., J. M. Schapiro, J. Lawrence, and T. C. Merigan. 1997. Genotypic and phenotypic analysis of the protease gene in HIV-1 infected patients that failed long-term saquinavir therapy and switched to other protease inhibitors, abstr. 17, p. 11. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Fla.
95. Wlodawer, A., and J. W. Erickson. 1993. Structure based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-580.
96. Wlodawer, A., M. Miller, M. Jaskolski, B. K. Sathyanarayana, E. Baldwin, I. T. Weber, L. M. Selk, L. Clawson, J. Schneider, and S. B. Kent. 1989. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245:616-621.
97. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J. Virol. 71:6662-6670.